Silexion Therapeutics (NASDAQ:SLXN) Releases Quarterly Earnings Results, Beats Estimates By $20.49 EPS

Silexion Therapeutics (NASDAQ:SLXN) released its earnings results on Tuesday. The company reported $19.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.17) by $20.49, FiscalAI reports.

Silexion Therapeutics Price Performance

SLXN stock opened at $1.53 on Thursday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97. Silexion Therapeutics has a 1 year low of $1.42 and a 1 year high of $22.36. The firm has a 50-day moving average of $1.82 and a 200 day moving average of $2.82. The company has a market cap of $4.79 million, a P/E ratio of -0.14 and a beta of -0.04.

Wall Street Analysts Forecast Growth

SLXN has been the subject of a number of analyst reports. Zacks Research upgraded shares of Silexion Therapeutics to a “hold” rating in a report on Tuesday, December 16th. Wall Street Zen cut Silexion Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Litchfield Hills Research assumed coverage on Silexion Therapeutics in a research note on Monday, December 15th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Silexion Therapeutics has a consensus rating of “Hold” and an average target price of $75.00.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.